CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

In 2025, CytomX remained focused on controlling costs and efficiently progressing its pipeline programs. Total operating expense for 2025 was $98.6 million compared to $113.1 million for 2024, a ...
IEEE

Revealing Herb-Symptom Associations and Mechanisms of Action in Protein Networks Using Subgraph Matching Learning

Abstract: In traditional Chinese medicine, deciphering herb-symptom associations (HSAs) and revealing their mechanisms of action are crucial for bridging traditional knowledge and modern biomedicine.
Targeted Oncology

A New Era in CTCL: The Dual-Action Potential of Denileukin Diftitox

The therapeutic landscape for cutaneous T-cell lymphoma (CTCL) is undergoing a significant shift with the emergence of denileukin diftitox (Lymphir), the first systemic treatment ...
OECD

EU Carbon Border Adjustment Mechanism: What is it, how does it work and what are the effects?

Analysis and insights for driving a rapid transition to net-zero while building resilience to physical climate impacts ...

Citius Oncology, Inc.: Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or ...

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data ...